The effort to
reduce obesity (and to profit from that effort) isn’t anything new, but based on my email inbox recently, perhaps we’re about to enter into an era of
blockbuster weight-management medications. For the moment, however, we’re at the early stages of any such race, and it looks like Novo Nordisk and Orexigen
are fighting for the strong start out of the gate.
In an era of
"publish or perish," combined with "fund or perish," we may be moving toward an era in which peer review is no longer up to the task, and we end up with
too many journals and too little rigor
The ability to create
isogenic cell lines in which the genome editing event is the sole differentiator between the phenotypes of two cells is a powerful tool. Despite all the
recent developments and improvements in targeting platforms, certain challenges remain, and the role played by the choice of cell line in order to achieve
success cannot be overstated.